The mechanisms involved, and possible treatment targets, in orofacial pain due to cancer are poorly understood. The aim of the first of this two-part series is to review the involved pathophysiological mechanisms and explore their possible roles in the orofacial region. However, there is a lack of relevant research in the trigeminal region, and we have therefore applied data accumulated from experiments on cancer pain mechanisms in rodent spinal models. In the second part, we review the clinical presentation of cancer-associated orofacial pain at various stages: initial diagnosis, during therapy (chemo-, radiotherapy, surgery), and in the post-therapy period. In the present article, we provide a brief outline of trigeminal functional neuro-anatomy and pain-modulatory pathways. Tissue destruction by invasive tumors (or metastases) induces inflammation and nerve damage, with attendant acute pain. In some cases, chronic pain, involving inflammatory and neuropathic mechanisms, may ensue. Distant, painful effects of tumors include paraneoplastic neuropathic syndromes and effects secondary to the release of factors by the tumor (growth factors, cytokines, and enzymes). Additionally, pain is frequent in cancer management protocols (surgery, chemotherapy, and radiotherapy). Understanding the mechanisms involved in cancer-related orofacial pain will enhance patient management.
Get full access to this article
View all access options for this article.
References
1.
Abbadie C, Brown JL, Mantyh PW, Basbaum AI (1996). Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience70:201–209.
2.
Aggarwal BB, Shishodia S, Ashikawa K, Bharti AC (2002). The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Curr Drug Targets Inflamm Allergy1:327–341.
3.
Ahmed SI, Thompson J, Coulson JM, Woll PJ (2000). Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol22:422–431.
4.
Alanen K, Deng DX, Chakrabarti S (2000). Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology36:161–167.
5.
Alvares D, Fitzgerald M (1999). Building blocks of pain: the regulation of key molecules in spinal sensory neurones during development and following peripheral axotomy. Pain Suppl6:S71–S85.
6.
Anderson PM, Schroeder G, Skubitz KM (1998). Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer83:1433–1439.
7.
Andreev N, Dimitrieva N, Koltzenburg M, McMahon SB (1995). Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. Pain63:109–115.
8.
Andrews DW, Silverman CL, Glass J, Downes B, Riley RJ, Corn BW, et al. (1995). Preservation of cranial nerve function after treatment of acoustic neurinomas with fractionated stereotactic radiotherapy. Preliminary observations in 26 patients. Stereotact Funct Neurosurg64:165–182.
Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, et al. (2001). Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer85:1759–1763.
11.
Ashina M, Bendtsen L, Jensen R, Olesen J (2000). Nitric oxide-induced headache in patients with chronic tension-type headache. Brain123(Pt 9):1830–1837.
12.
Babenko V, Svensson P, Graven-Nielsen T, Drewes AM, Jensen TS, Arendt-Nielsen L (2000). Duration and distribution of experimental muscle hyperalgesia in humans following combined infusions of serotonin and bradykinin. Brain Res853:275–281.
Banning A, Sjogren P, Henriksen H (1991). Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain45:45–48.
15.
Bantick SJ, Wise RG, Ploghaus A, Clare S, Smith SM, Tracey I (2002). Imaging how attention modulates pain in humans using functional MRI. Brain125(Pt 2):310–319.
16.
Basbaum AI, Fields HL (1984). Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci7:309–338.
17.
Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA (1990). Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA87:1620–1624.
18.
Bederson JB, Fields HL, Barbaro NM (1990). Hyperalgesia during naloxone-precipitated withdrawal from morphine is associated with increased on-cell activity in the rostral ventromedial medulla. Somatosens Mot Res7:185–203.
19.
Bennett A, Carter RL, Stamford IF, Tanner NS (1980). Prostaglandin-like material extracted from squamous carcinomas of the head and neck. Br J Cancer41:204–208.
20.
Benoliel R, Eliav E, Tal M (2001). No sympathetic nerve sprouting in rat trigeminal ganglion following painful and non-painful infraorbital nerve neuropathy. Neurosci Lett297:151–154.
21.
Benoliel R, Eliav E, Tal M (2002a). Strain-dependent modification of neuropathic pain behaviour in the rat hindpaw by a priming painful trigeminal nerve injury. Pain97:203–212.
22.
Benoliel R, Wilensky A, Tal M, Eliav E (2002b). Application of a pro-inflammatory agent to the orbital portion of the rat infraorbital nerve induces changes indicative of ongoing trigeminal pain. Pain99:567–578.
23.
Benoliel R, Sharav Y, Tal M, Eliav E (2003). Management of chronic orofacial pain: today and tomorrow. Compend Contin Educ Dent24:909–920, 922–924, 926–928 passim.
24.
Bergstrom P, Johnsson A, Bergenheim T, Henriksson R (1999). Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. J Neurooncol42:13–21.
25.
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. (2004). Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med350:1945–1952.
26.
Bhattacharya SK, Das N, Rao PJ (1988). Brain monoamines during carrageenan-induced acute paw inflammation in rats. J Pharm Pharmacol40:518–520.
27.
Blair HC, Athanasou NA (2004). Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol19:189–199.
28.
Bongenhielm U, Yates JM, Fried K, Robinson PP (1998). Sympathectomy does not affect the early ectopic discharge from myelinated fibres in ferret inferior alveolar nerve neuromas. Neurosci Lett245:89–92.
29.
Bongenhielm U, Boissonade FM, Westermark A, Robinson PP, Fried K (1999). Sympathetic nerve sprouting fails to occur in the trigeminal ganglion after peripheral nerve injury in the rat. Pain82:283–288.
30.
Boughton-Smith NK, Deakin AM, Follenfant RL, Whittle BJ, Garland LG (1993). Role of oxygen radicals and arachidonic acid metabolites in the reverse passive Arthus reaction and carrageenin paw oedema in the rat. Br J Pharmacol110:896–902.
31.
Bouhassira D, Danziger N, Attal N, Guirimand F (2003). Comparison of the pain suppressive effects of clinical and experimental painful conditioning stimuli. Brain126(Pt 5):1068–1078.
32.
Bruch-Gerharz D, Ruzicka T, Kolb-Bachofen V (1998). Nitric oxide in human skin: current status and future prospects. J Invest Dermatol110:1–7.
33.
Cain DM, Wacnik PW, Eikmeier L, Beitz A, Wilcox GL, Simone DA (2001). Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. Pain Med2:15–23.
34.
Caraceni A, Portenoy RK (1999). An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain82:263–274.
35.
Carter RL (1985). Patterns and mechanisms of localized bone invasion by tumors: studies with squamous carcinomas of the head and neck. Crit Rev Clin Lab Sci22:275–315.
36.
Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. (2002). Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol20:3478–3483.
37.
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature389:816–824.
38.
Cavaletti G, Bogliun G, Crespi V, Marzorati L, Zincone A, Marzola M, et al. (1997). Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol15:199–206.
39.
Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003). Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer98:822–831.
40.
Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. (1999). Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res59:991–994.
41.
Chen AM, Bucci MK, Singer MI, Garcia J, Kaplan MJ, Chan AS, et al. (2007). Intraoperative radiation therapy for recurrent head-and-neck cancer: the UCSF experience. Int J Radiat Oncol Biol Phys67:122–129.
42.
Chiang CY, Hu JW, Sessle BJ (1994). Parabrachial area and nucleus raphe magnus-induced modulation of nociceptive and nonnociceptive trigeminal subnucleus caudalis neurons activated by cutaneous or deep inputs. J Neurophysiol71:2430–2445.
43.
Clohisy DR, Ramnaraine ML, Scully S, Qi M, Van G, Tan HL, et al. (2000). Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J Orthop Res18:967–976.
44.
Clohisy DR, O’Keefe PF, Ramnaraine ML (2001). Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice. J Orthop Res19:554–558.
45.
Coleman RE (1998). How can we improve the treatment of bone metastases further? Curr Opin Oncol10(Suppl 1):S7–S13.
46.
Coward K, Plumpton C, Facer P, Birch R, Carlstedt T, Tate S, et al. (2000). Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states. Pain85:41–50.
47.
Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH (1992). The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol107:660–664.
48.
Cunha JM, Cunha FQ, Poole S, Ferreira SH (2000). Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J Pharmacol130:1418–1424.
49.
Dahlof B, Gustafsson D, Hedner T, Jern S, Hansson L (1990). Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens8:811–817.
50.
Dallel R, Duale C, Molat JL (1998). Morphine administered in the substantia gelatinosa of the spinal trigeminal nucleus caudalis inhibits nociceptive activities in the spinal trigeminal nucleus oralis. J Neurosci18:3529–3536.
51.
Danziger N, Gautron M, Le Bars D, Bouhassira D (2001a). Activation of diffuse noxious inhibitory controls (DNIC) in rats with an experimental peripheral mononeuropathy. Pain91:287–296.
52.
Danziger N, Weil-Fugazza J, Le Bars D, Bouhassira D (2001b). Stage-dependent changes in the modulation of spinal nociceptive neuronal activity during the course of inflammation. Eur J Neurosci13:230–240.
53.
Davar G (2001). Endothelin-1 and metastatic cancer pain. Pain Med2:24–27.
54.
Davar G, Hans G, Fareed MU, Sinnott C, Strichartz G (1998). Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport9:2279–2283.
55.
Davidson EM, Coggeshall RE, Carlton SM (1997). Peripheral NMDA and non-NMDA glutamate receptors contribute to nociceptive behaviors in the rat formalin test. Neuroreport8:941–946.
56.
DeLeo JA, Yezierski RP (2001). The role of neuroinflammation and neuroimmune activation in persistent pain. Pain90:1–6.
57.
DeLeo JA, Colburn RW, Nichols M, Malhotra A (1996). Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res16:695–700.
58.
Devor M, Wall PD (1990). Cross-excitation in dorsal root ganglia of nerve-injured and intact rats. J Neurophysiol64:1733–1746.
59.
Devor M, Keller CH, Deerinck TJ, Levinson SR, Ellisman MH (1989). Na+ channel accumulation on axolemma of afferent endings in nerve end neuromas in Apteronotus. Neurosci Lett102:149–154.
60.
Devor M, Wall PD, Catalan N (1992). Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain48:261–268.
61.
Doubell TP, Mannion RJ, Woolf CJ (1999). The dorsal horn: state-dependent sensory processing, plasticity and the generation of pain. In: Textbook of pain. Wall PD, Melzack R, editors. London, UK: Churcill Livingstone, pp. 165–181.
62.
Droy-Lefaix MT, Drouet Y, Geraud G, Hosford D, Braquet P (1991). Superoxide dismutase (SOD) and the PAF-antagonist (BN 52021) reduce small intestinal damage induced by ischemia-reperfusion. Free Radic Res Commun12–13(Pt 2):725–735.
63.
Duale C, Raboisson P, Molat JL, Dallel R (2001). Systemic morphine reduces the wind-up of trigeminal nociceptive neurons. Neuroreport12:2091–2096.
64.
Dubner R, Ren K (1999). Endogenous mechanisms of sensory modulation. Pain Suppl6:S45–S53.
65.
Duhamel G, Parlier Y (1982). [Protective effect of isaxonine against vincristine-induced neuropathy (article in French; author’s transl)]. Nouv Presse Med11:1254–1256.
66.
Eliav E, Benoliel R, Tal M (2001). Inflammation with no axonal damage of the rat saphenous nerve trunk induces ectopic discharge and mechanosensitivity in myelinated axons. Neurosci Lett311:49–52.
67.
Eliav E, Teich S, Benoliel R, Nahlieli O, Lewkowicz AA, Baruchin A, et al. (2002). Large myelinated nerve fiber hypersensitivity in oral malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod94:45–50.
68.
Eliav E, Tal M, Benoliel R (2004). Experimental malignancy in the rat induces early hypersensitivity indicative of neuritis. Pain110:727–737.
69.
England JD, Happel LT, Kline DG, Gamboni F, Thouron CL, Liu ZP, et al. (1996). Sodium channel accumulation in humans with painful neuromas. Neurology47:272–276.
70.
Epstein JB, Stewart KH (1993). Radiation therapy and pain in patients with head and neck cancer. Eur J Cancer B Oral Oncol29:191–199.
71.
Epstein JB, Emerton S, Kolbinson DA, Le ND, Phillips N, Stevenson-Moore P, et al. (1999). Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck21:1–11.
72.
Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P (2001a). Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck23:389–398.
73.
Epstein JB, Silverman S Jr, Paggiarino DA, Crockett S, Schubert MM, Senzer NN, et al. (2001b). Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer92:875–885.
74.
Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R (2007). Orofacial pain in cancer: Part II—clinical perspectives and management. J Dent Res86:xxx–xxx.
75.
Farber L, Haus U, Spath M, Drechsler S (2004). Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol Suppl119:2–8.
76.
Fayad L, Keating MJ, Reuben JM, O’Brien S, Lee BN, Lerner S, et al. (2001). Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood97:256–263.
77.
Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C (1996). Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel—a phase II study. Cancer Chemother Pharmacol39:150–156.
78.
Foley KM (1985). The treatment of cancer pain. N Engl J Med313:84–95.
79.
Foley KM (1999). Advances in cancer pain (review). Arch Neurol56:413–417.
80.
Foley KM, Inturrisi CE (1987). Analgesic drug therapy in cancer pain: principles and practice. Med Clin North Am71:207–232.
81.
Forman AD (2004). Peripheral neuropathy and cancer. Curr Oncol Rep6:20–25.
82.
Fosslien E (2000). Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci30:3–21.
83.
Fujimiya K, Sugihara K, Nishikawa T (1997). Experimental study on the role of osteoclasts and free radicals in the mandibular invasion of VX2 carcinoma in Japanese white rabbits. Bone20:245–250.
84.
Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C (1998). The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain78:157–169.
85.
Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002). Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol29(5 Suppl 15):21–33.
86.
Gao WQ, Dybdal N, Shinsky N, Murnane A, Schmelzer C, Siegel M, et al. (1995). Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol38:30–37.
87.
Gill JS, Windebank AJ (1998a). Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest101:2842–2850.
88.
Gill JS, Windebank AJ (1998b). Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ5:876–883.
89.
Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, et al. (1992). Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol10:795–803.
90.
Grond S, Zech D, Diefenbach C, Radbruch L, Lehmann KA (1996). Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain64:107–114.
91.
Grudt TJ, Williams JT, Travagli RA (1995). Inhibition by 5-hydroxytryptamine and noradrenaline in substantia gelatinosa of guinea-pig spinal trigeminal nucleus. J Physiol485(Pt 1):113–120.
92.
Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, et al. (1999). Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. Cancer Chemother Pharmacol43:68–72.
93.
Hayakawa K, Itoh T, Niwa H, Yamamoto M, Liang Y, Doyu M, et al. (1999). Nerve growth factor prevention of aged-rat sympathetic neuron injury by cisplatin, vincristine and taxol—in vitro explant study. Neurosci Lett274:103–106.
94.
Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK (2002). Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res8:1284–1291.
95.
Hilkens PH, ven den Bent MJ (1997). Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst2:350–361.
96.
Hilkens PH, Pronk LC, Verweij J, Vecht CJ, van Putten WL, van den Bent MJ (1997a). Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer75:417–422.
97.
Hilkens PH, Verweij J, Vecht CJ, Stoter G, van den Bent MJ (1997b). Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol8:187–190.
98.
Hill EL, Turner R, Elde R (1991). Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats. Neuroscience44:747–755.
99.
Holthusen H, Arndt JO (1994). Nitric oxide evokes pain in humans on intracutaneous injection. Neurosci Lett165:71–74.
100.
Honore P, Mantyh PW (2000). Bone cancer pain: from mechanism to model to therapy. Pain Med1:303–309.
101.
Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, et al. (2000a). Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med6:521–528.
102.
Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, et al. (2000b). Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience98:585–598.
103.
Hunt SP, Mantyh PW (2001). The molecular dynamics of pain control. Nat Rev Neurosci2:83–91.
104.
Hurley RW, Hammond DL (2000). The analgesic effects of supraspinal mu and delta opioid receptor agonists are potentiated during persistent inflammation. J Neurosci20:1249–1259.
105.
Jackson DV, Wells HB, Atkins JN, Zekan PJ, White DR, Richards F 2nd, et al. (1988). Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med84:1016–1022.
106.
Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, et al. (2003). Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol1:274–278.
107.
Jonakait GM (1993). Neural-immune interactions in sympathetic ganglia. Trends Neurosci16:419–423.
108.
Julius D, Basbaum AI (2001). Molecular mechanisms of nociception. Nature413:203–210.
109.
Kang MY, Holland JM, Stevens KR Jr (2000). Cranial neuropathy following curative chemotherapy and radiotherapy for carcinoma of the nasopharynx. J Laryngol Otol114:308–310.
110.
Kanner R (2001). Diagnosis and management of neuropathic pain in patients with cancer. Cancer Invest19:324–333.
111.
Kessler W, Kirchhoff C, Reeh PW, Handwerker HO (1992). Excitation of cutaneous afferent nerve endings in vitro by a combination of inflammatory mediators and conditioning effect of substance P. Exp Brain Res91:467–476.
112.
Kim HJ, Na HS, Sung B, Nam HJ, Chung YJ, Hong SK (1999). Is sympathetic sprouting in the dorsal root ganglia responsible for the production of neuropathic pain in a rat model? Neurosci Lett269:103–106.
113.
Kim SH, Na HS, Sheen K, Chung JM (1993). Effects of sympathectomy on a rat model of peripheral neuropathy. Pain55:85–92.
114.
King BF, Ziganshina LE, Pintor J, Burnstock G (1996). Full sensitivity of P2X2 purinoceptor to ATP revealed by changing extracellular pH. Br J Pharmacol117:1371–1373.
115.
Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M (2003). Tumor hypoxia: a target for selective cancer therapy. Cancer Sci94:1021–1028.
116.
Klegeris A, Walker DG, McGeer PL (1997). Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. J Neuroimmunol78:152–161.
117.
Koeller JM (1990). Understanding cancer pain. Am J Hosp Pharm47(Suppl):S3–S6.
118.
Kolbinson DA, Schubert MM, Flournoy N, Truelove EL (1988). Early oral changes following bone marrow transplantation. Oral Surg Oral Med Oral Pathol66:130–138.
119.
Kress M, Sommer C (2004). Neuroimmunology and pain: peripheral effects of proinflammatory cytokines. In: Hyperalgesia: molecular mechanisms and clinical implications. Progress in pain research and management. Vol. 30. Brune K, Handwerker HO, editors. Seattle: IASP Press, pp. 57–66.
120.
Kumazawa T, Mizumura K, Minagawa M, Tsujii Y (1991). Sensitizing effects of bradykinin on the heat responses of the visceral nociceptor. J Neurophysiol66:1819–1824.
121.
Kundu N, Yang Q, Dorsey R, Fulton AM (2001). Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer93:681–686.
122.
Kurbel S, Kurbel B, Kovacic D, Sulava D, Krajina Z, Dmitrovic B, et al. (1999). Endothelin-secreting tumors and the idea of the pseudoectopic hormone secretion in tumors. Med Hypotheses52:329–333.
123.
Kurebayashi J (2000). Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications. Breast Cancer7:124–129.
124.
Kurzrock R (2001). Cytokine deregulation in cancer. Biomed Pharmacother55:543–547.
125.
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell93:165–176.
126.
Lagueny A, Rommel A, Vignolly B, Taieb A, Vendeaud-Busquet M, Doutre MS, et al. (1986). Thalidomide neuropathy: an electrophysiologic study. Muscle Nerve9:837–844.
Le Bars D, Dickenson AH, Besson JM (1979). Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain6:283–304.
129.
LeCouteur RA, Gillette EL, Powers BE, Child G, McChesney SL, Ingram JT (1989). Peripheral neuropathies following experimental intraoperative radiation therapy (IORT). Int J Radiat Oncol Biol Phys17:583–590.
130.
Lee KM, Kang BS, Lee HL, Son SJ, Hwang SH, Kim DS, et al. (2004). Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. Eur J Neurosci19:3375–3381.
131.
Levine JD, Reichling DB (1999). Peripheral mechanisms of inflammatory pain. In: Textbook of pain. Wall PD, Melzack R, editors. Edinburgh: Churchill Livingstone, pp. 59–84.
132.
Lewin GR, Rueff A, Mendell LM (1994). Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci6:1903–1912.
133.
Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO (2002). Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck24:792–799.
134.
Lindenlaub T, Sommer C (2003). Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol (Berl)105:593–602.
135.
Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, et al. (2002). Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res8:2306–2310.
136.
Lischetzki G, Rukwied R, Handwerker HO, Schmelz M (2001). Nociceptor activation and protein extravasation induced by inflammatory mediators in human skin. Eur J Pain5:49–57.
137.
Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A, et al. (1997). Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer5:126–129.
138.
Love S, Jacobs JM, Myers R (1986). Chronic demyelination in mouse peripheral nerve produced by lysophosphatidyl choline and x-irradiation: ultrastructural observations. J Neurocytol15:155–167.
139.
Luger NM, Honore P, Sabino MA, Schwei MJ, Rogers SD, Mach DB, et al. (2001). Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res61:4038–4047.
140.
Luyk NH, Hammond-Tooke G, Bishara SN, Ferguson MM (1991). Facial pain and muscle atrophy secondary to an intracranial tumour. Br J Oral Maxillofac Surg29:204–207.
141.
Mabuchi T, Matsumura S, Okuda-Ashitaka E, Kitano T, Kojima H, Nagano T, et al. (2003). Attenuation of neuropathic pain by the nociceptin/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production. Eur J Neurosci17:1384–1392.
142.
Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD, et al. (2002). Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience113:155–166.
143.
Malan TP Jr, Porreca F (2005). Lipid mediators regulating pain sensitivity. Prostaglandins Other Lipid Mediat77:123–130.
144.
Mamet J, Baron A, Lazdunski M, Voilley N (2002). Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J Neurosci22:10662–10670.
145.
Mandell-Brown M, Johnson JT, Rabin BS, Hamill E, Wagner RL (1986). Neck node immunoreactivity in head and neck carcinoma. Otolaryngol Head Neck Surg95:500–506.
146.
Mannix K, Ahmedzai SH, Anderson H, Bennett M, Lloyd-Williams M, Wilcock A (2000). Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care. Palliat Med14:455–461.
147.
Martelletti P, Giacovazzo M (1996). Putative neuroimmunological mechanisms in cluster headache. An integrated hypothesis. Headache36:312–315.
148.
Martin HA, Basbaum AI, Kwiat GC, Goetzl EJ, Levine JD (1987). Leukotriene and prostaglandin sensitization of cutaneous high-threshold C- and A-delta mechanonociceptors in the hairy skin of rat hindlimbs. Neuroscience22:651–659.
149.
Marx RE, Johnson RP (1987). Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol64:379–390.
150.
Matata BM, Galinanes M (2002). Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding activity. J Biol Chem277:2330–2335.
151.
Matzner O, Devor M (1994). Hyperexcitability at sites of nerve injury depends on voltage-sensitive Na+ channels. J Neurophysiol72:349–359.
152.
McCarthy GM, Skillings JR (1992). Jaw and other orofacial pain in patients receiving vincristine for the treatment of cancer. Oral Surg Oral Med Oral Pathol74:299–304.
153.
McLachlan EM, Janig W, Devor M, Michaelis M (1993). Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature363:543–546.
154.
McMahon SB, Wall PD (1988). Descending excitation and inhibition of spinal cord lamina I projection neurons. J Neurophysiol59:1204–1219.
155.
Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, et al. (2002). A rat model of bone cancer pain. Pain96:129–140.
156.
Melis M, Zawawi K, al-Badawi E, Lobo Lobo S, Mehta N (2002). Complex regional pain syndrome in the head and neck: a review of the literature. J Orofac Pain16:93–104.
157.
Mercadante S (1997). Malignant bone pain: pathophysiology and treatment. Pain69:1–18.
158.
Mestre JR, Chan G, Zhang F, Yang EK, Sacks PG, Boyle JO, et al. (1999). Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann NY Acad Sci889:62–71.
159.
Millan MJ (1999). The induction of pain: an integrative review. Prog Neurobiol57:1–164.
160.
Millan MJ (2002). Descending control of pain. Prog Neurobiol66:355–474.
161.
Mizobuchi K, Kincaid J (2003). Accessory neuropathy after high-dose radiation therapy for tongue-base carcinoma. Muscle Nerve28:650–651.
162.
Mohan S, Epstein JB (2003). Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol39:537–546.
163.
Morgan MM, Gogas KR, Basbaum AI (1994). Diffuse noxious inhibitory controls reduce the expression of noxious stimulus-evoked Fos-like immunoreactivity in the superficial and deep laminae of the rat spinal cord. Pain56:347–352.
164.
Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. (1998). RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun253:395–400.
165.
Ness TJ, Gebhart GF (1991). Interactions between visceral and cutaneous nociception in the rat. II. Noxious visceral stimuli inhibit cutaneous nociceptive neurons and reflexes. J Neurophysiol66:29–39.
166.
Neumann S, Doubell TP, Leslie T, Woolf CJ (1996). Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature384:360–364.
167.
Novakovic SD, Eglen RM, Hunter JC (2001). Regulation of Na+ channel distribution in the nervous system. Trends Neurosci24:473–478.
168.
Ogunrinde OK, Lunsford LD, Flickinger JC, Kondziolka DS (1995). Cranial nerve preservation after stereotactic radiosurgery for small acoustic tumors. Arch Neurol52:73–79.
169.
Otsuki T, Yamada O, Yata K, Sakaguchi H, Kurebayashi J, Yawata Y, et al. (2000). Expression and production of interleukin 10 in human myeloma cell lines. Br J Haematol111:835–842.
170.
Peters CM, Lindsay TH, Pomonis JD, Luger NM, Ghilardi JR, Sevcik MA, et al. (2004). Endothelin and the tumorigenic component of bone cancer pain. Neuroscience126:1043–1052.
171.
Pitcher GM, Yashpal K, Coderre TJ, Henry JL (1995). Mechanisms underlying antinociception provoked by heterosegmental noxious stimulation in the rat tail-flick test. Neuroscience65:273–281.
172.
Ploghaus A, Becerra L, Borras C, Borsook D (2003). Neural circuitry underlying pain modulation: expectation, hypnosis, placebo. Trends Cogn Sci7:197–200.
173.
Porreca F, Burgess SE, Gardell LR, Vanderah TW, Malan TP Jr, Ossipov MH, et al. (2001). Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the micro-opioid receptor. J Neurosci21:5281–5288.
174.
Rabin BM, Meyer JR, Berlin JW, Marymount MH, Palka PS, Russell EJ (1996). Radiation-induced changes in the central nervous system and head and neck. Radiographics16:1055–1072.
175.
Ren K, Dubner R (2002). Descending modulation in persistent pain: an update. Pain100:1–6.
176.
Rocher FP, Sentenac I, Berger C, Marquis I, Romestaing P, Gerard JP (1995). Stereotactic radiosurgery: the Lyon experience. Acta Neurochir Suppl63:109–114.
177.
Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M (1980). Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst64:1061–1070.
178.
Rosano L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, et al. (2003). Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res63:2447–2453.
179.
Rybak LP, Husain K, Whitworth C, Somani SM (1999). Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system. Toxicol Sci47:195–202.
180.
Sabino MA, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, et al. (2002). Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res62:7343–7349.
181.
Sabino MA, Luger NM, Mach DB, Rogers SD, Schwei MJ, Mantyh PW (2003). Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer104:550–558.
182.
Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, et al. (2001). Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature410:471–475.
183.
Sarlani E, Schwartz AH, Greenspan JD, Grace EG (2003). Facial pain as first manifestation of lung cancer: a case of lung cancer-related cluster headache and a review of the literature. J Orofac Pain17:262–267.
184.
Sato J, Suzuki S, Tamura R, Kumazawa T (1994). Norepinephrine excitation of cutaneous nociceptors in adjuvant-induced inflamed rats does not depend on sympathetic neurons. Neurosci Lett177:135–138.
185.
Sawamoto N, Honda M, Okada T, Hanakawa T, Kanda M, Fukuyama H, et al. (2000). Expectation of pain enhances responses to nonpainful somatosensory stimulation in the anterior cingulate cortex and parietal operculum/posterior insula: an event-related functional magnetic resonance imaging study. J Neurosci20:7438–7445.
186.
Schafers M, Lee DH, Brors D, Yaksh TL, Sorkin LS (2003). Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J Neurosci23:3028–3038.
187.
Scholz J, Woolf CJ (2002). Can we conquer pain? Nat Neurosci5(Suppl):1062–1067.
188.
Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, et al. (1999). Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci19:10886–10897.
189.
Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J, et al. (2001). Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood98:2269–2271.
190.
Seltzer Z, Devor M (1979). Ephaptic transmission in chronically damaged peripheral nerves. Neurology29:1061–1064.
191.
Serre CM, Farlay D, Delmas PD, Chenu C (1999). Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone25:623–629.
192.
Sessle BJ (2000). Acute and chronic craniofacial pain: brainstem mechanisms of nociceptive transmission and neuroplasticity, and their clinical correlates. Crit Rev Oral Biol Med11:57–91.
193.
Sessle BJ (2005). Peripheral and central mechanisms of orofacial pain and their clinical correlates. Minerva Anestesiol71:117–136.
194.
Sessle BJ, Hu JW, Amano N, Zhong G (1986). Convergence of cutaneous, tooth pulp, visceral, neck and muscle afferents onto nociceptive and non-nociceptive neurones in trigeminal subnucleus caudalis (medullary dorsal horn) and its implications for referred pain. Pain27:219–235.
195.
Seybold VS, Jia YP, Abrahams LG (2003). Cyclo-oxygenase-2 contributes to central sensitization in rats with peripheral inflammation. Pain105:47–55.
196.
Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC (2003). RANK ligand and osteoprotegerin in myeloma bone disease. Blood101:2094–2098.
197.
Simone DA, Cain DM (2004). Tumor-peripheral nerve interactions in a model of cancer pain. In: Hyperalgesia: molecular mechanisms and clinical implications. Progress in pain research and management. Vol. 30. Brune K, Handwerker HO, editors. Seattle: IASP Press, pp. 129–140.
198.
Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET (2001). Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev12:33–40.
199.
Smith WC, Bourne D, Squair J, Phillips DO, Chambers WA (1999). A retro -spective cohort study of post mastectomy pain syndrome. Pain83:91–95.
200.
Sonis ST (2004). The pathobiology of mucositis. Nat Rev Cancer4:277–284.
201.
Sonis ST, Scherer J, Phelan S, Lucey CA, Barron JE, O’Donnell KE, et al. (2002). The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Prolif35(Suppl 1):93–102.
202.
Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. (2004). Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer100(9 Suppl):1995–2025.
203.
Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, et al. (2002). Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood100:3002–3007.
204.
Steen KH, Issberner U, Reeh PW (1995). Pain due to experimental acidosis in human skin: evidence for non-adapting nociceptor excitation. Neurosci Lett199:29–32.
205.
Su CY, Lui CC (1996). Perineural invasion of the trigeminal nerve in patients with nasopharyngeal carcinoma. Imaging and clinical correlations. Cancer78:2063–2069.
206.
Suzuki R, Kontinen VK, Matthews E, Williams E, Dickenson AH (2000). Enlargement of the receptive field size to low intensity mechanical stimulation in the rat spinal nerve ligation model of neuropathy. Exp Neurol163:408–413.
207.
Taiwo YO, Heller PH, Levine JD (1990). Characterization of distinct phospholipases mediating bradykinin and noradrenaline hyperalgesia. Neuroscience39:523–531.
208.
Tal M, Eliav E (1996). Abnormal discharge originates at the site of nerve injury in experimental constriction neuropathy (CCI) in the rat. Pain64:511–518.
209.
Tanaka M, Cummins TR, Ishikawa K, Dib-Hajj SD, Black JA, Waxman SG (1998). SNS Na+ channel expression increases in dorsal root ganglion neurons in the carrageenan inflammatory pain model. Neuroreport9:967–972.
210.
Tanner KD, Levine JD, Topp KS (1998). Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol395:481–492.
211.
Tassorelli C, Greco R, Wang D, Sandrini M, Sandrini G, Nappi G (2003). Nitroglycerin induces hyperalgesia in rats—a time-course study. Eur J Pharmacol464:159–162.
212.
Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, et al. (1998). The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron21:531–543.
213.
Topp KS, Tanner KD, Levine JD (2000). Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol424:563–576.
214.
Urch C (2004). The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med18:267–274.
215.
Urch CE, Donovan-Rodriguez T, Dickenson AH (2003). Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain. Pain106:347–356.
216.
van Deventer H, Bernard S (1999). Use of gabapentin to treat taxane-induced myalgias. J Clin Oncol17:434–435.
217.
van Wilgen CP, Dijkstra PU, van der Laan BF, Plukker JT, Roodenburg JL (2004). Morbidity of the neck after head and neck cancer therapy. Head Neck26:785–791.
218.
Verge VM, Xu Z, Xu XJ, Wiesenfeld-Hallin Z, Hokfelt T (1992). Marked increase in nitric oxide synthase mRNA in rat dorsal root ganglia after peripheral axotomy: in situ hybridization and functional studies. Proc Natl Acad Sci USA89:11617–11621.
219.
Voges J, Kocher M, Runge M, Poggenborg J, Lehrke R, Lenartz D, et al. (2006). Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study. Cancer107:1355–1364.
220.
Vos BP, Benoist JM, Gautron M, Guilbaud G (2000). Changes in neuronal activities in the two ventral posterior medial thalamic nuclei in an experimental model of trigeminal pain in the rat by constriction of one infraorbital nerve. Somatosens Mot Res17:109–122.
221.
Vujaskovic Z (1997). Structural and physiological properties of peripheral nerves after intraoperative irradiation. J Peripher Nerv Syst2:343–349.
222.
Wacnik PW, Eikmeier LJ, Ruggles TR, Ramnaraine ML, Walcheck BK, Beitz AJ, et al. (2001). Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci21:9355–9366.
223.
Wacnik PW, Kehl LJ, Trempe TM, Ramnaraine ML, Beitz AJ, Wilcox GL (2003). Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain101:175–186.
Wagner R, Myers RR (1996b). Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience73:625–629.
226.
Wagner R, Janjigian M, Myers RR (1998). Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression. Pain74:35–42.
227.
Watkins LR, Maier SF (2002). Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev82:981–1011.
228.
Watkins LR, Maier SF, Goehler LE (1995). Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain63:289–302.
229.
Watkins LR, Milligan ED, Maier SF (2001). Glial activation: a driving force for pathological pain. Trends Neurosci24:450–455.
230.
Waxman SG, Cummins TR, Dib-Hajj S, Fjell J, Black JA (1999). Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. Muscle Nerve22:1177–1187.
231.
Waxman SG, Dib-Hajj S, Cummins TR, Black JA (2000). Sodium channels and their genes: dynamic expression in the normal nervous system, dysregulation in disease states (1). Brain Res886:5–14.
232.
Westlund KN, Sun YC, Sluka KA, Dougherty PM, Sorkin LS, Willis WD (1992). Neural changes in acute arthritis in monkeys. II. Increased glutamate immunoreactivity in the medial articular nerve. Brain Res Brain Res Rev17:15–27.
233.
Whalley ET, Clegg S, Stewart JM, Vavrek RJ (1989). Antagonism of the algesic action of bradykinin on the human blister base. Adv Exp Med Biol247(A):261–268.
Wokke JH, van Dijk GW (1997). Sensory neuropathies including painful and toxic neuropathies. J Neurol244:209–221.
236.
Woolf CJ (1996). Phenotypic modification of primary sensory neurons: the role of nerve growth factor in the production of persistent pain. Philos Trans R Soc Lond B Biol Sci351:441–448.
237.
Woolf CJ, Salter MW (2000). Neuronal plasticity: increasing the gain in pain. Science288:1765–1769.
238.
Woolf CJ, Shortland P, Coggeshall RE (1992). Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature355:75–78.
239.
Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J (1994). Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience62:327–331.
240.
Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S (1997). Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol121:417–424.
241.
Yang CY, Meng CL, Liao CL, Wong PY (2003). Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines. Prostaglandins Other Lipid Mediat72:115–130.
242.
Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, et al. (2003). A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA100:10954–10959.
